C
rohn's disease (CD) is a chronic, inflammatory disorder commonly associated with nutritional and vitamin deficiencies. 1, 2 It is a lifelong disease treated with a multidisciplinary approach to include nutritional support, immunosuppression, and surgical resection. 3 Historically, studies have shown that CD is associated with increased lipid oxidation and smaller body habitus, particularly during periods of high disease activity. 4, 5 Patients with CD have been shown to have a lower lean body mass than controls. 6 Rates of obesity in the United States are increasing. According to the Centers for Disease Control, 34.9% of adults are obese (defined as a body mass index [BMI] greater than 30 kg/m 2 ), and 16.9% of children are obese. 7 The prevalence of obesity has remained constant since 2003, 7 and studies have shown an increase in rates of obesity in patients with CD. 8 A recent study performed on the adult inflammatory bowel disease (IBD) population of Tayside, Scotland, revealed that 18% of patients were obese (compared with 23% of healthy subjects) and 38% were overweight (similar to healthy subjects). 9 A study from the ImproveCareNow collective for pediatric IBD showed 20.0% of pediatric patients with CD were overweight or obese. 10 The effect of obesity on the chronic inflammation of CD is unknown. CD has been associated with increased intraabdominal fat which has been implicated in synthesis of tumor necrosis factor a (TNF-a); however, this is not necessarily associated with increased BMI. 11 Mesenteric, "creeping fat" involved in CD is molecularly different than the extra adipose tissue in obese patients. 12 Limited data are available characterizing obesity in CD. In a retrospective study, obese women were 1.6 times more likely to have CD than their counterparts with normal BMI. 13 Additional studies have shown that overweight patients with CD present at a later age and have a shorter time to surgery than those who were underweight, 14 although a larger recent study showed no difference in time to surgery. 15 Other studies showed that patients who were obese showed a decrease in time to perianal complications. 9, 16 In a prospective study of 170,805 female patients, high fat intake was not associated with development of CD, 17 and a different prospective study of 300,724 patients showed no increase in incident CD in patients with increased BMI. 18 Higher BMI has not been shown to correlate well with higher C-reactive protein (CRP) levels. 15 Patients with morbid obesity were shown to be more likely to have isolated colonic disease when compared with nonobese patients. 19 Studies and guidelines are lacking for management of patients with CD and obesity. Obesity has been shown to be associated with lack or loss of response to anti-TNF-a medications. 20, 21 Bariatric surgery for morbid obesity in patients with CD reduced CRP levels, and reduced steroid use, and increased rates of remission with reduction in necessary drug doses. 22 The aim of this study was to assess characteristics of CD associated with being overweight or obese.
METHODS
This is a retrospective review of the electronic health records (to include endoscopy and pathology reports) of adult patients older than 18 years with confirmed CD presenting to the IBD clinic at Walter Reed National Military Medical Center from June 1, 2011 to June 1, 2013. This is a subspecialty gastroenterology clinic staffed with 14 rotating gastroenterology fellows and 2 gastroenterologists with interest and specific training in management of IBD. Patients were excluded with a diagnosis of indeterminate colitis or if their diagnosis of CD was still in question.
For each patient, data regarding their CD were extracted from the electronic health record. This included age, race, sex, Montreal classification (disease location, disease behavior, and duration of disease), 23 BMI, disease activity (classified by endoscopic severity and physician's global assessment [PGA]), serum erythrocyte sedimentation rate, serum CRP, smoking history, intestinal surgery history (to include indication and location), maintenance medications, and extraintestinal manifestations (EIMs). PGA was classified as either active disease or disease in remission. Patients were classified by their highest BMI over the course of the study. The closest temporal assessment of dynamic patient characteristics such as PGA, erythrocyte sedimentation rate, and CRP to patients' highest BMIs were used.
Patients were described as underweight if their BMI was less than 20 kg/m 2 , as normal weight if their BMI was greater than or equal to 20 kg/m 2 but less than 25 kg/m 2 , as overweight if their BMI was greater than or equal to 25 kg/m 2 but less than 30 kg/m 2 , and as obese if their BMI was greater than 30 kg/m 2 .
Each BMI subgroup was characterized independently; comparisons between groups were made for CD behaviors or characteristics. Data were collated and analyzed using statistical software package IBM SPSS Statistics 21.0 (IBM, Armonk, NY). Demographic and clinical characteristics were presented using means and SDs for continuous variables and counts with proportions for categorical variables. Fisher exact test and chisquared test were used for analysis between group comparisons of categorical data. Independent-Samples t test and 1-way analysis of variance were used to compare continuous data. Levene's test was used to assess equality of variances among groups. A probability value less than 0.05 was considered statistically significant.
RESULTS
Two hundred nine records of patients with CD were examined. Of the patients examined, 51.7% were male, 68.9% were white, and average age was 43.4 6 14.9 years (Table 1) ; 52.6% had ileocolonic disease and 25.4% had penetrating disease (Table 2) . Seventy patients (33.5%) had perianal disease, 30 patients (14.4%) had proximal disease (upper gastrointestinal modifiers), and 44 patients (21.1%) had EIMs. One hundred four patients (49.8%) were being managed with anti-TNF-a drugs (infliximab, adalimumab, or certolizumab pegol). Of our study patients, 54.1% were active duty or formerly active duty; the remainder were military dependents; there was no significant differences in obesity rates between the 2 populations (26.0% dependent versus 23.9% active duty, P ¼ 0.842).
The average BMI of our patients was 26. As BMI increased, serum erythrocyte sedimentation rate (P ¼ 0.020) and CRP (P ¼ 0.004) decreased (Table 3 ). There was no relationship between BMI and history of small bowel resection (P ¼ 0.925).
The most common EIM seen was arthralgias (50%), followed by erythema nodosum (13.6%) and inflammatory arthritis (13.6%) ( Table 4) . With increasing BMI, patients were more likely to have any EIM (P ¼ 0.003). When assessing only nonarthralgia EIMs, this relationship held constant (P ¼ 0.047). Logistic regression analysis revealed an increase in EIMs associated with a higher duration of disease (P ¼ 0.012) (Fig. 1) .
DISCUSSION
In this single-center, retrospective study, most patients with CD were overweight or obese (66%), which is consistent with national trends of the general population. Although many studies have shown that there is a large population of patients with CD who have high BMIs, our cohort of aggressively managed patients has an alarming rate of obesity. This adds to the growing literature that obesity is even a problem of patients with malabsorptive conditions. By both PGA and inflammatory markers, patients with higher BMIs tended to have less active disease. This is intuitive, given the higher levels of lipid oxidation in patients with active disease; we expect that patients who are underweight have more active inflammation. It is difficult to determine whether patients with active disease lose weight because of metabolic changes and lipolysis, decreased PO intake to avoid symptoms, or malabsorption. Our study shows that location of disease plays a larger role in weight modulation than disease behavior likely because of the absorption responsibilities of the small bowel or symptoms of postprandial pain or early satiety associated with upper tract involvement. This suggests that weight modulation in patients with CD is influenced by both absorptive surface area and decreased oral intake more than lipid oxidation increased by inflammation. Proximal disease was significantly more common in our underweight patients. Evaluating patients for proximal disease with upper endoscopy is commonly done in patients who have upper gastrointestinal symptoms (e.g., dyspepsia, reflux) rather than those patients who exhibit malabsorption or anorexia. Interestingly, obese patients are more likely to have gastroesophageal reflux disease; this may lead gastroenterologists to pursue upper endoscopy to evaluate these patients. Yet, in our patients, obese patients were less likely to have proximal disease. Our data suggest that upper endoscopy and/or a high sensitivity small bowel study-such as capsule endoscopy, computed tomography enterography, or magnetic resonance enterography -to evaluate for proximal disease may be considered in underweight patients with CD who have trouble maintaining a healthy weight.
Patients with obesity were more likely to have a diverse group of EIMs of disease. Although obese patients are more likely to have arthralgias secondary to a higher incidence of osteoarthritis, obese patients were more likely to have EIMs even after arthralgias were removed from the analysis. The reason for this finding is unclear and not previously reported. An increase in 21, [24] [25] [26] These findings include a decreased response to infliximab in obese patients, which, given that infliximab is dosed by weight, suggests that adipose tissue may negatively affect efficacy of anti-inflammatory drugs. EIMs are discovered as a result of patients' symptoms, so there is not a viable way to screen for EIMs in patients with high BMI. However, future studies may explore the effect of weight loss strategies on the severity of EIMs. Our study has many strengths. We had a large number of patients with a significant obese population allowing for strong statistical comparisons. Our patients have equal access to health care, given their TRICARE beneficiary status, which provided a diverse population in age, race, sex, and even socioeconomic status. Patients also had a diverse phenotype of CD both in location and behavior, and we had a significant population (49.8%) requiring biologic therapy. Finally, all patients were managed by 2 gastroenterologists with a specific interest in IBD and were the beneficiaries of care within current standards.
Our study had some limitations. It was a retrospective study of health records, and data collection was limited by information available in inpatient and outpatient electronic medical record and did not include acutely sick inpatients. BMI, although the only measure of obesity available in our records, is an inexact way to describe extra adipose tissue as waist-to-hip ratio may provide a better measure of centripetal obesity. 27, 28 Although PGA is not an objective assessment of patients' disease status, it is interesting that physicians were more likely to state that obese patients were in remission than underweight patients, despite the lack of correlation with endoscopic or histologic activity. Patients with CD have historically been described as "thin," and perhaps physicians see obese patients with CD as having less severe disease. However, PGA in our clinic was validated given that patients described as having active disease also had higher serum levels of inflammatory markers. Unlike other studies, 16 we did not find that perianal disease was more common in obese patients. However, in Blain's study, only 3% of the study population was obese and was then characteristic matched to twice as many nonobese patients with CD. Our study's 25% obese population may resemble the current population better. Further study into the relationship between perianal disease and obesity may help clarify this correlation.
Obesity is increasing among patient with CD and is presenting with unique management dilemmas. Patients with CD present difficult challenges because their risk of nutritional and vitamin deficiency, which may mean they do not receive adequate counseling on weight loss. Gastroenterologists should be prepared to counsel patients with Crohn's disease regarding weight loss in a manner similar to other chronic diseases commonly seen in the gastrointestinal clinic. Overweight and obese patients may require special attention with regards to the diagnosis and treatment of EIMs.
